Skip to main content

Eating Disorders

0
Pipeline Programs
5
Companies
9
Clinical Trials
6 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Forte Biosciences
3 programs
A Longitudinal Study of Severe and Enduring Eating DisordersN/A1 trial
Radically Open Dialectical Behavior TherapyN/A1 trial
Unfolding Severe and Enduring Eating Disorders (U-SEED)N/A1 trial
Active Trials
NCT06752304Recruiting800Est. Dec 2048
NCT06792071Recruiting18Est. Jul 2027
NCT06592963Recruiting50Est. Apr 2026
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
3 programs
Body ProjectN/A1 trial
Dissonance-based eating disorder prevention programN/A1 trial
Internet-based DBIN/A1 trial
Active Trials
NCT01126918Completed432Est. Feb 2016
NCT00663754Completed306Est. Oct 2012
NCT02567890Completed443Est. Jun 2019
Electromedical Products International
1 program
Alpha-Stim AIDN/A1 trial
Active Trials
NCT07017322Recruiting30Est. Nov 2027
MediLink Therapeutics
MediLink TherapeuticsChina - Suzhou
1 program
Enhanced Body-Swap for Anorexia NervosaN/A1 trial
Active Trials
NCT06799962Recruiting80Est. Jan 2026
Gloria Biosciences
Gloria BiosciencesChina - Guangzhou
1 program
MIT-EDN/A1 trial
Active Trials
NCT06693089Recruiting64Est. Feb 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Electromedical Products InternationalAlpha-Stim AID
Forte BiosciencesRadically Open Dialectical Behavior Therapy
MediLink TherapeuticsEnhanced Body-Swap for Anorexia Nervosa
Gloria BiosciencesMIT-ED
Forte BiosciencesA Longitudinal Study of Severe and Enduring Eating Disorders
Forte BiosciencesUnfolding Severe and Enduring Eating Disorders (U-SEED)
Oregon TherapeuticsInternet-based DBI
Oregon TherapeuticsBody Project
Oregon TherapeuticsDissonance-based eating disorder prevention program

Clinical Trials (9)

Total enrollment: 2,223 patients across 9 trials

NCT07017322Electromedical Products InternationalAlpha-Stim AID

Non-invasive Cranial Electrical Stimulation for Mealtime Anxiety in Adults With Eating Disorders

Start: Jun 2025Est. completion: Nov 202730 patients
N/ARecruiting
NCT06792071Forte BiosciencesRadically Open Dialectical Behavior Therapy

Evaluation of Radically Open Dialectical Behavior Therapy for Youth At Risk for Developing Severe and Enduring Eating Disorders

Start: Feb 2025Est. completion: Jul 202718 patients
N/ARecruiting
NCT06799962MediLink TherapeuticsEnhanced Body-Swap for Anorexia Nervosa

AI and VR Devices for Eating Behavior Rehabilitation

Start: Jan 2025Est. completion: Jan 202680 patients
N/ARecruiting
NCT06693089Gloria BiosciencesMIT-ED

Metacognitive Interpersonal Therapy Across Transdiagnostic Eating Disorders, Including Underweight

Start: Nov 2024Est. completion: Feb 202664 patients
N/ARecruiting
NCT06752304Forte BiosciencesA Longitudinal Study of Severe and Enduring Eating Disorders

A Longitudinal Study of Severe and Enduring Eating Disorders

Start: Sep 2024Est. completion: Dec 2048800 patients
N/ARecruiting
NCT06592963Forte BiosciencesUnfolding Severe and Enduring Eating Disorders (U-SEED)

Unfolding Severe and Enduring Eating Disorders (U-SEED)

Start: Jun 2024Est. completion: Apr 202650 patients
N/ARecruiting
NCT02567890Oregon TherapeuticsInternet-based DBI

Swedish Body Project for Prevention of Eating Disorders

Start: Sep 2015Est. completion: Jun 2019443 patients
N/ACompleted
NCT01126918Oregon TherapeuticsBody Project

Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students

Start: Apr 2010Est. completion: Feb 2016432 patients
N/ACompleted
NCT00663754Oregon TherapeuticsDissonance-based eating disorder prevention program

Effectiveness of a Dissonance-Based Eating Disorder Prevention Program (The Body Project II)

Start: Mar 2005Est. completion: Oct 2012306 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 actively recruiting trials targeting 2,223 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.